Metabolic syndrome and risk of in-stent restenosis: Clinical outcomes in patients undergoing percutaneous coronary intervention

Korean Circulation Journal

Volumn 37, Issue 11, 2007, Pages 567-573

  Jae, Kyung Ha ^a   Dong, Cheul Han ^a   Ki, Won Hwang ^a   Dong, Won Lee ^a   Yung, Kwon Yun ^a   Han, Cheol Lee ^a   Kim, Jun ^a   June, Hong Kim ^a   Kook, Jin Chun ^a   Taek, Jong Hong ^a   Yung, Woo Shin ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Coronary restenosis; Metabolic syndrome; Stent

Indexed keywords

HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IMPLANTATION; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 37749021288     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2007.37.11.567     Document Type: Article

References (21)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1. diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
4. Kasper. Harrison's Principles of Internal Medicine. 16th ed. McGraw-Hill; 2005. p.2158.
5. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
7. Ch BS, Kim HJ. Metabolic syndrome and cardiovascular disease. Korean Circ J 2003;33:645-52.
8. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
9. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
10. Rana JS, Monraats PS, Zwinderman AH, et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care 2005;28:873-7.
11. West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004;109:867-73.
12. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005;112:2792-8.
13. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004;27:2654-60.
14. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Ko GT, Cockram CS, Chow CC, et al. High prevalence of metabolic syndrome in Hong Kong Chinese: comparison of three diagnostic criteria. Diabetes Res Clin Pract 2005;69:160-8.
16. Abaci A, Oguzhan A, Kahraman S, et al. Effects of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-42.
17. Turhan H, Yasar AS, Erbay AR, Yetkin E, Sasmaz H, Sabah I. Impaired coronary collateral vessel development in patients with metabolic syndrome. Coron Artery Dis 2005;16:281-5.
18. Solymoss BC, Bourassa MG, Lesperance J, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis 2003;14:207-12.
19. Hsia J, Bittner V, Tripputi M, Howard BV. Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial. Am Heart J 2003;146: 439-45.
20. Yoo TW, Sung KC, Kim YC. The relationship of the hypertension, insulin resistance and metabolic syndrome in the serum ruic acid level. Korean Circ J 2004;34:874-82.
21. Marroquin OC, Kip KE, Kelley DE, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004;109:714-21.